BioRay Pharmaceutical gets China NMPA’s nod for clinical trial of BRY812
During pre-clinical pharmacological studies, BRY812 showed considerable antitumour activity in multiple tumour models
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 May 23
During pre-clinical pharmacological studies, BRY812 showed considerable antitumour activity in multiple tumour models
25 May 23
With an extensive pipeline focused on DDR and strategic partnerships with global pharmaceutical companies, Artios has chosen ANGLE…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 May 23
Under the terms of the license agreement, UCB will utilize ClearPoint Neuro’s proprietary technology and services in connection…
25 May 23
The agreement gives Adalvo exclusive rights to register, commercialise and distribute Mellozzan in these countries
24 May 23
Post-merger, the combined firm, which is expected to operate as TuHURA Biosciences and trade on Nasdaq Capital Market,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 May 23
Managed by the Foundation for the National Institutes of Health (FNIH), the consortium aims to accelerate the process…
24 May 23
Danyelza is said to be a recombinant humanised, monoclonal antibody that targets the ganglioside GD2, highly expressed in…
24 May 23
ModeX will gain access to Nona Bioscience’s fully human Harbour Mice platforms to discover monoclonal antibodies that will…
24 May 23
The partnership is aimed at creating groundbreaking therapies for rare genetic disorders, as well as widely prevalent cardiometabolic…
24 May 23
In the 12-month period ending in December 2022, over 79,000 people in the U.S. were reported to have…